Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1979 1
1980 3
1981 2
1982 1
1983 1
1984 2
1985 2
1986 2
1987 3
1988 9
1989 3
1990 3
1991 5
1992 8
1993 8
1994 6
1995 11
1996 4
1997 11
1998 7
1999 9
2000 10
2001 9
2002 17
2003 11
2004 9
2005 17
2006 15
2007 13
2008 9
2009 15
2010 7
2011 10
2012 6
2013 4
2014 6
2015 6
2016 10
2017 4
2018 10
2019 6
2020 15
2021 17
2022 12
2023 5
Text availability
Article attribute
Article type
Publication date

Search Results

321 results
Results by year
Filters applied: . Clear all
Page 1
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT).
Tada H, Mitsudomi T, Misumi T, Sugio K, Tsuboi M, Okamoto I, Iwamoto Y, Sakakura N, Sugawara S, Atagi S, Takahashi T, Hayashi H, Okada M, Inokawa H, Yoshioka H, Takahashi K, Higashiyama M, Yoshino I, Nakagawa K; West Japan Oncology Group. Tada H, et al. Among authors: sugio k. J Clin Oncol. 2022 Jan 20;40(3):231-241. doi: 10.1200/JCO.21.01729. Epub 2021 Nov 2. J Clin Oncol. 2022. PMID: 34726958 Clinical Trial.
Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.
Kenmotsu H, Yamamoto N, Yamanaka T, Yoshiya K, Takahashi T, Ueno T, Goto K, Daga H, Ikeda N, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Tsuboi M. Kenmotsu H, et al. Among authors: sugio k. J Clin Oncol. 2020 Jul 1;38(19):2187-2196. doi: 10.1200/JCO.19.02674. Epub 2020 May 14. J Clin Oncol. 2020. PMID: 32407216 Clinical Trial.
Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy.
Takahashi T, Sakai K, Kenmotsu H, Yoh K, Daga H, Ohira T, Ueno T, Aoki T, Hayashi H, Yamazaki K, Hosomi Y, Chen-Yoshikawa TF, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Akamatsu H, Seto T, Saeki S, Sugio K, Nishio M, Inokawa H, Yamamoto N, Nishio K, Tsuboi M. Takahashi T, et al. Among authors: sugio k. Cancer Sci. 2022 Jan;113(1):287-296. doi: 10.1111/cas.15171. Epub 2021 Nov 7. Cancer Sci. 2022. PMID: 34689382 Free PMC article. Clinical Trial.
Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
Tanaka K, Asahina H, Kishimoto J, Miyata Y, Uchida T, Watanabe K, Hamai K, Harada T, Tsubata Y, Sugawara S, Kobayashi K, Sugio K, Oizumi S, Okamoto I. Tanaka K, et al. Among authors: sugio k. Eur J Cancer. 2021 May;149:14-22. doi: 10.1016/j.ejca.2021.02.019. Epub 2021 Apr 1. Eur J Cancer. 2021. PMID: 33813328 Clinical Trial.
A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801).
Asahina H, Tanaka K, Morita S, Maemondo M, Seike M, Okamoto I, Oizumi S, Kagamu H, Takahashi K, Kikuchi T, Isobe T, Sugio K, Kobayashi K. Asahina H, et al. Among authors: sugio k. Clin Lung Cancer. 2021 Mar;22(2):147-151. doi: 10.1016/j.cllc.2020.09.023. Epub 2020 Oct 16. Clin Lung Cancer. 2021. PMID: 33199228 Clinical Trial.
A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L).
Yamaguchi H, Wakuda K, Fukuda M, Kenmotsu H, Mukae H, Ito K, Chibana K, Inoue K, Miura S, Tanaka K, Ebi N, Suetsugu T, Harada T, Kirita K, Yokoyama T, Nakatani Y, Yoshimura K, Nakagawa K, Yamamoto N, Sugio K. Yamaguchi H, et al. Among authors: sugio k. J Thorac Oncol. 2021 Dec;16(12):2121-2132. doi: 10.1016/j.jtho.2021.07.026. Epub 2021 Aug 19. J Thorac Oncol. 2021. PMID: 34419684 Free article. Clinical Trial.
[Interstitial pneumonitis].
Hirai F, Toyokawa G, Ohba T, Kitajima H, Yamaguchi M, Maruyama R, Hamatake M, Seto T, Sugio K, Ichinose Y. Hirai F, et al. Among authors: sugio k. Gan To Kagaku Ryoho. 2011 Nov;38(11):1782-4. Gan To Kagaku Ryoho. 2011. PMID: 22083185 Japanese.
Resistance to gefitinib.
Uramoto H, Sugio K, Oyama T, Sugaya M, Hanagiri T, Yasumoto K. Uramoto H, et al. Among authors: sugio k. Int J Clin Oncol. 2006 Dec;11(6):487-91. doi: 10.1007/s10147-006-0609-y. Epub 2006 Dec 25. Int J Clin Oncol. 2006. PMID: 17180521
Incidentally proven pulmonary "ALKoma".
Osoegawa A, Nosaki K, Miyamoto H, Kometani T, Hirai F, Ondo K, Seto T, Sugio K, Choi YL, Soda M, Mano H, Ichinose Y. Osoegawa A, et al. Among authors: sugio k. Intern Med. 2010;49(6):603-6. doi: 10.2169/internalmedicine.49.3126. Epub 2010 Mar 15. Intern Med. 2010. PMID: 20228600 Free article.
321 results